Oncolytics Biotech ONCY 深 滬
等待開盤 09-25 09:30:00 美东时间
0.672
-0.004
-0.67%
華盛通- 最 高0.685
- 今 開0.6765
- 成交量 98.59万股
- 最 低 0.6419
- 昨 收 0.6765
- 總市值 8568.71万
- 52周最高 1.42
- 市盈率 靜 --
- 換手率 0.77%
- 52周最低 0.6419
- 委 比 -81.82%
- 總股本 1.28亿
- 歷史最高 6.037
- 量 比 1.08
- 振 幅 6.37%
- 歷史最低 0.3258
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oncolytics Biotech Reports Positive Pelareorep Preclinical Results
The latest announcement is out from Oncolytics Biotech ( ($ONCY) ). On Septembe...
09-10 20:48
Oncolytics Biotech Announces Pelareorep Lowered Tumor Growth Compared To Control During Initial Treatment Period
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the initial...
09-10 20:16
美股大行评级 | 潜在涨幅1610.53%！Ascendiant Capital上调Alzamend Neuro目标价至26美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Alzamend Neuro"买入"评级，目标价从25美元升至26美元；Tigress Financial：维持Legence"买入"评级，目标价从125美元升至130美元
08-20 08:39
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) with a Buy and lowers the price target from $10 to $5.
08-19 20:37
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
Oncolytics Biotech received FDA feedback supporting the potential expansion of its REO 033 study into a pivotal Part B, which could enable accelerated approval based on objective response rate and progression-free survival for full approval. The FDA suggested an End-of-Phase meeting to finalize the registration program, prompting the company to cancel its planned Type D meeting. The feedback aligns with the proposed study design and development p...
08-18 13:00
Oncolytics Biotech(ONCY.US)获FDA快速通道资格 将迎关键监管会议
经济观察网 Oncolytics Biotech Inc.（ONCY）旗下pelareorep相关研发及商业化布局推进，获FDA快速通道资格及新专利，后续将召开...
07-31 21:56
Oncolytics Biotech Faces Nasdaq Minimum Bid Price Noncompliance
Oncolytics Biotech ( ($ONCY) ) has issued an update. On July 20, 2026, Oncolyti...
07-25 04:56
Oncolytics Biotech shares are trading higher after the company announced that it received FDA Fast Track Designation for pelareorep evaluation in certain forms of colorectal cancer.
Oncolytics Biotech shares are trading higher after the company announced that it received FDA Fast Track Designation for pelareorep evaluation in certain forms of colorectal cancer.
07-13 23:03
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Oncolytics Biotech Inc. provided an update on its REO 033 clinical trial evaluating pelareorep for the treatment of RAS-mutant, microsatellite stable metastatic colorectal cancer. Half of the planned clinical sites will be activated this month, with over 20 patients already identified. The company plans to hold a Type D meeting with the FDA to discuss adding Part B to the trial, which aims to support both accelerated and full approval. Part A of ...
07-13 13:00
Oncolytics Biotech Receives New U.S. Patent For Its Proprietary Manufacturing Process For Pelareorep
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in ...
06-16 21:02
